Table 1 (abstract P370). See text for description
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
Mean Age at onset | 8.5 years (1.5-17) |
Sex Ratio (M : F) | 1.3 : 1 |
Average delay between disease onset and diagnosis | 9 months |
Fever at Onset | 7 / 14 (50%) |
Recurrent Oral Ulceration | 13 / 14 (93%) |
Genital ulceration | 9 / 14 (64%) |
Skin Lesions | 7 / 14 (50%) |
Musculoskeletal involvement (arthritis) | 8 / 14 ( 57% ) |
Eye involvement | 5 / 14 (35%) |
Anterior Uveitis | 3 / 5 (60%) |
Intermediate Uveitis | 1 / 5 (20%) |
Pan Uveitis | 2 / 5 (40%) |
GI Involvement | 5 / 14 (35%) |
CNS | 2 / 14 (14%) |
CVS (pericardial effusion) | 1 / 14 (7%) |
RS ( bronchiectasis) | 1 / 14 (7%) |
Positive HLA B51 | 8 / 12 (67%) |
Favourable response to medications used in our patients | |
 Colchicine | 2 / 8 (25%) |
 Methotrexate | 1 / 8 (12.5%) |
 Thalidomide | 2 / 5 (40%) |
 Azathioprine | 4 / 7 (57%) |
 Subcutaneous Adalimumab | 2 /3 (67%) |
 Intravenous Tocilizumab | 0 / 1 (0%) |
 Average number of flares on tapering medication | 2 |
 Inactive disease on last follow up | 13 / 14 (93%) |
 Lost on follow up during CoVID-19 Pandemic | 6 / 14 (43%) |
 Resistant Chronic Disease | 1 / 14 ( 7% ) |